Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Non-Current Assets (2020 - 2025)

Tarsus Pharmaceuticals has reported Non-Current Assets over the past 6 years, most recently at $39.4 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $39.4 million for Q4 2025, up 94.1% from a year ago — trailing twelve months through Dec 2025 was $112.8 million (up 81.08% YoY), and the annual figure for FY2025 was $39.4 million, up 94.1%.
  • Non-Current Assets for Q4 2025 was $39.4 million at Tarsus Pharmaceuticals, up from $32.9 million in the prior quarter.
  • Over the last five years, Non-Current Assets for TARS hit a ceiling of $39.4 million in Q4 2025 and a floor of $2.4 million in Q3 2022.
  • Median Non-Current Assets over the past 5 years was $7.0 million (2023), compared with a mean of $11.1 million.
  • Biggest five-year swings in Non-Current Assets: dropped 28.19% in 2022 and later skyrocketed 279.35% in 2023.
  • Tarsus Pharmaceuticals' Non-Current Assets stood at $3.0 million in 2021, then fell by 15.8% to $2.5 million in 2022, then surged by 276.21% to $9.4 million in 2023, then soared by 116.73% to $20.3 million in 2024, then surged by 94.1% to $39.4 million in 2025.
  • The last three reported values for Non-Current Assets were $39.4 million (Q4 2025), $32.9 million (Q3 2025), and $20.6 million (Q2 2025) per Business Quant data.